nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Achieving equitable care in pulmonary embolism: exploring the potential of pulmonary embolism response teams
|
Sul, Lidiya V. |
|
|
9 |
1 |
p. 166-168 |
artikel |
2 |
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
|
Brown, Fiona C. |
|
|
9 |
1 |
p. 127-131 |
artikel |
3 |
AIHA and rituximab: time for Pneumocystis prophylaxis?
|
Hansen, Dennis Lund |
|
|
9 |
1 |
p. 229-230 |
artikel |
4 |
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
|
Castaño-Díez, Sandra |
|
|
9 |
1 |
p. 39-53 |
artikel |
5 |
Back from (BTKi) holiday
|
Brander, Danielle M. |
|
|
9 |
1 |
p. 222-223 |
artikel |
6 |
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
|
Valtis, Yannis K. |
|
|
9 |
1 |
p. 151-161 |
artikel |
7 |
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
|
Jeremy, Erin |
|
|
9 |
1 |
p. 1-14 |
artikel |
8 |
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow
|
Zhao, Kai |
|
|
9 |
1 |
p. 209-221 |
artikel |
9 |
Control of antigen-independent T-cell migration after HSCT
|
Koyama, Motoko |
|
|
9 |
1 |
p. 207-208 |
artikel |
10 |
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
|
Autore, Francesco |
|
|
9 |
1 |
p. 162-165 |
artikel |
11 |
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
|
Avigan, Zachary M. |
|
|
9 |
1 |
p. 202-206 |
artikel |
12 |
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment
|
Ren, Kehan |
|
|
9 |
1 |
p. 54-65 |
artikel |
13 |
Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid
|
Sim, Derek S. |
|
|
9 |
1 |
p. 180-191 |
artikel |
14 |
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
|
Lachey, Jennifer |
|
|
9 |
1 |
p. 193-201 |
artikel |
15 |
Factor XI inhibitors: a new class of anticoagulants
|
Connors, Jean M. |
|
|
9 |
1 |
p. 192 |
artikel |
16 |
Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel
|
Mirza, Adil |
|
|
9 |
1 |
p. 29-38 |
artikel |
17 |
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE
|
Camus, Vincent |
|
|
9 |
1 |
p. 101-115 |
artikel |
18 |
Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
|
Ferri, Grace M. |
|
|
9 |
1 |
p. 78-88 |
artikel |
19 |
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.
|
|
|
|
9 |
1 |
p. 169 |
artikel |
20 |
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
|
Chen, Lucia Y. |
|
|
9 |
1 |
p. 176-179 |
artikel |
21 |
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study
|
Maese, Luke |
|
|
9 |
1 |
p. 66-77 |
artikel |
22 |
Respiratory phenotype and health care utilization patterns by adults with sickle cell disease
|
Agawu, Atu |
|
|
9 |
1 |
p. 143-150 |
artikel |
23 |
Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study
|
Zadro, Yoann |
|
|
9 |
1 |
p. 231-238 |
artikel |
24 |
Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow
|
Lykins, Joshua |
|
|
9 |
1 |
p. 15-28 |
artikel |
25 |
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
|
Bajwa, Amneet |
|
|
9 |
1 |
p. 170-175 |
artikel |
26 |
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
|
Espinosa-Cotton, Madelyn |
|
|
9 |
1 |
p. 116-126 |
artikel |
27 |
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding
|
Sims, Matthew C. |
|
|
9 |
1 |
p. 132-142 |
artikel |
28 |
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
|
Shanafelt, Tait D. |
|
|
9 |
1 |
p. 224-228 |
artikel |
29 |
Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
|
Pechlivani, Nikoletta |
|
|
9 |
1 |
p. 89-100 |
artikel |